• RWB is set to release its Q3 financial results on November 29, 2021
• A conference call will follow this release on November 30, 2021, at 5:00 PM ET to discuss these results, the company’s operations, upcoming events, and a Q&A session
• A replay of the call will be available for 90 days, starting three hours after the conclusion
• RWB is increasingly optimistic about its Q3 performance following growth in revenue from Q1 to Q2, along with strategic investments that would allow for Q3 growth

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) just announced that it will be releasing its third-quarter (“Q3”) 2021 financial results on Monday, November 29, 2021, after market close. The company will also hold management discussions and analyses (“MD&A”) and other subsequent events following the release (https://ibn.fm/6MuEP). This will mark Christopher Ecken’s first financial release, having joined RWB as its new Chief Financial Officer (“CFO”) back in October 2021 (https://ibn.fm/Xze2a). A conference call is also scheduled for Tuesday, November 30, 2021, at 5:00 PM ET. Here, Brad Rogers, RWB’s Chief Executive Officer (“CEO”), will introduce Mr. Ecken, after which they will discuss the company’s Q3 2021 results, operations, and upcoming events. The conference will also feature a Q&A session with the company’s management, during which attendees will have the opportunity to ask them questions on various topics, including the company’s Q3 financial performance. RWB is optimistic about its Q3 performance. During the Q2 2021 announcement back in August 2021, Mr. Rogers was keen to acknowledge that the company was making significant strides that would play an integral role in its Q3 financial performance. “We continue to make great strides with our branded products and see momentum in Q2, which has teed up Q3 nicely, and will translate into a strong second half,” he noted. “In Florida, after closing the acquisition at the end of April, we have made strategic investments that are allowing us to quickly ramp up capacity as well as complete construction for new store openings before the end of 2021,” he added (https://ibn.fm/FfHav). Mr. Rogers announced that revenue for the second quarter was up by 13% from the previous quarter, along with several significant raw material inventory purchases geared towards supporting growth for Q3, in anticipation of new branded product line launches. Those interested in the announcement can listen online and ask questions via this webcast link:  https://ibn.fm/hQoeY. (Questions during the Q&A will be accepted only via this link.) Dial-in numbers for the conference call for listening only are:

1. 877-705-6006
2. 201-689-8557

A recording of the call will be available approximately three hours following the conference call at https://ir.redwhitebloom.com/  The call will also be available for replay for 90 days, starting three hours after the conclusion of the call. Simply dial 877-660-6853 or 201-612-7415 and enter access ID: 13725118. Going forward, RWB will be announcing dates of earnings reports 30 days before their release. This is one of several new operating procedures to be implemented by Christopher Ecken, RWB’s new CFO. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating
• The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity
• Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs
• The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders

There is no denying that food is a massive part of the holiday season. With this year’s Thanksgiving celebration kicking off the fall-winter holiday season that will stretch until New Year’s Day, Americans are likely to go all out foodwise, as is tradition. However, for people with eating disorders, the holiday season can constitute a major challenge. “Holidays may trigger eating disordered behaviors and disordered eating due to the set of stressors that the holidays present; relationship stress, travel, finances, and holiday fatigue are the usual culprits,” explains Cecille Ahrens, a psychotherapist and addiction specialist (https://ibn.fm/kflMr). Research suggests that stress pushes people living with eating disorders, including binge-eating disorder (“BED”), toward overeating as they seek to escape from reality and self-awareness. Unfortunately, this means that this year’s holiday season, as with all others before it, may exacerbate the situation among those suffering from eating disorders, causing them to eat even more. At the same time, the fall-winter holiday season can also adversely impact those suffering from chronic pain. Winter, which comes with changes in temperature, pressure, and moisture, can cause chronic pain patients to experience more aches, stiffness, and a limited range of motion. According to the Pontchartrain Orthopedics & Sports Medicine organization, this heightened achiness considerably increases patients’ pain (https://ibn.fm/Yrp8X). The issue is further compounded by the fact that existing FDA-approved chronic pain drugs have limited efficacy and/or significant side effects. Fortunately, positive change may be in the offing for people living with these conditions. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company pursuing the development of novel bioscience solutions that aim to address indications with high unmet needs, is leading the next wave of psychedelic drug development with a laser focus on chronic pain, eating disorders, and other unique conditions. The company has made significant progress as it advances toward the rollout of multiple Phase 2a clinical studies to be conducted in collaboration with the University of Michigan and the University of Florida. The studies will evaluate the safety and preliminary effectiveness of Tryp’s TRP-8802, a non-proprietary 25 mg oral capsule of synthetic psilocybin, for the treatment of fibromyalgia, phantom limb pain syndrome, complex regional pain syndrome, BED, and hypothalamic obesity. In line with a recent response to its Investigational New Drug (“IND”) application, Tryp will focus enrollment of the initial Phase 2a study on patients with BED. In addition, the company will submit an IND application for a separate Phase 2a study evaluating TRP-8802 with hypothalamic obesity (https://ibn.fm/LvpL3). Earlier in November, Tryp also submitted an IND application to evaluate the safety and preliminary effectiveness of TRP-8802 in a Phase 2a clinical trial involving patients with fibromyalgia, a class of chronic pain. Tryp anticipates initiating this study next year subject to a favorable review of the IND application (https://ibn.fm/tTavr). Tryp has already received IND authorization for a Phase 2a clinical trial in phantom limb pain, a type of chronic pain (https://ibn.fm/YpmjK). Tryp expects to use data from the multiple Phase 2a studies, as well as various data sets to support the use of TRP-8803, its proprietary psilocybin-based drug product with a novel route of administration, in Phase 2b studies. Eventually, the company intends to commercialize its drug product, potentially easing the challenges and difficulties that eating disorder patients and people suffering from chronic pain face during the holiday seasons. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• U.S.-based FingerMotion is a technology innovator focused on smart communication applications in China’s mobile-hungry billion-plus population
• The company’s big data services are relatively new in development but already play a significant role in the insurtech industry’s global growth trends
• While most of FingerMotion’s revenues are derived from its SMS and MMS products, executives anticipate its big data services will eventually be the company’s largest driver of profits
• The insurtech industry has already generated record annual deal-making this year as of the third quarter, outpacing all of 2020 by 48 percent

The insurtech industry has turned 2021 into a record year for business, with deals that have already outpaced all of 2020, by approximately 48 percent, as of the end of the third quarter. Analysts at CBInsights reported insurtechs had raised $10.5 billion across 427 deals by the quarter’s end (https://ibn.fm/tyVjH). China communications technology solutions provider FingerMotion (OTCQX: FNGR) plays a part in the trend, inking a big data outlook deal with global insurer Pacific Life early in the year to provide data analytics for Pacific Life’s Re-insurance division, and adding two brands last month that will generate value-add underwriting services by covering mobile consumer device maintenance needs (https://ibn.fm/5CGwk). FingerMotion’s revenue generator is its mobile device tech services division, which grew 142 percent year-over-year in its Telecommunications Products and Services business sector and 25 percent quarterly in its SMS (texting) and MMS (phone photo, video and audio sharing) sectors as of the most recent financial report in October (https://ibn.fm/iZHMG). But the company anticipates the latest insurtech services will begin to come online early next year and generate new revenue channels in several of China’s provinces. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” CEO Martin Shen stated last month following the financial report. “This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin.” FingerMotion’s trademarked big data platform, Sapientus, provides the power behind the company’s services, handling over half a million transactions daily for its mobile payment and recharge services. Although based in the U.S., FingerMotion is focused on the emerging potential of China’s billion-plus population, more than half of which is avid about communications technology to the point of boosting mobile phone subscriptions higher than the country’s actual total population because of the many consumers that use multiple phones. More than 750 million are described as proximity mobile payment users who pay for goods or services using a mobile phone while visiting in-person at a point-of-sale terminal (https://ibn.fm/tKgGM). Ninety percent of smartphone users in the country want their next device to be 5G-enabled, according to a review by China Internet Watch (https://ibn.fm/bfd4D). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
• The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
• Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
• InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
• Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://ibn.fm/LRrGu). On October 13, InMed closed the previously announced (https://ibn.fm/rj9qS) acquisition of BayMedica Inc., in a transaction that created an industry leader in the manufacture and commercialization of rare cannabinoids. The integrated teams are now working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. “For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol(R) CBC (cannabichromene) and progressing our existing programs,” commented Eric A. Adams, InMed President and CEO. The management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products, in addition to expanding revenues substantially in the short-to-medium term. Further, the integrated science teams will be looking to explore the therapeutic potential of BayMedica’s novel cannabinoid analogs for incorporation into InMed’s pharmaceutical drug development. With regards to its proprietary IntegraSyn(TM) cannabinoid manufacturing approach, the team is currently focused on process optimization for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cannabinoids. InMed holds that IntegraSyn will be a preferred pharmaceutical production method and may fit perfectly with BayMedica’s chemical synthesis and biosynthesis manufacturing approaches for non-pharmaceutical applications. In addition, September 30 also marked the beginning of the 755-201-EB study, InMed’s Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). The commencement of the study marked the first time cannabinol has advanced to a Phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment. The study, which has ethics and regulatory authority approvals in five countries and is expected to take place across seven countries, namely Austria, Germany, Greece, France, Italy, Israel, and Serbia, follows two completed Phase 1 studies. The Phase 1 studies strongly evidenced the overall safety and tolerability of the INM-755 cream. In addition, preclinical data showed that the cream might help relieve characteristic EB symptoms, including pain and inflammation, as well as potentially restore the skin’s integrity in some EB Simplex patients. Combined, the activities related to the INM-755 clinical trials contributed to the company’s increased research and development (“R&D”) expenses for Q1 2022, which stood at $1.5 million, up from $0.9 million in Q1 2021. InMed has also developed a cannabinol (“CBN”) topical eye drop formulation, INM-088, currently the subject of preclinical studies as a potential treatment for glaucoma. Data from these studies demonstrate CBN’s effectiveness in reducing cell death in retinal ganglion cells, indicating the cannabinoid’s neuroprotective capabilities that may extend vision retention. In addition, preclinical data suggest that CBN reduces intraocular pressure in glaucoma models. On August 17, the company presented at the H.C. Wainwright Ophthalmology Conference detailing these findings. InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088. Other key highlights of the report and business update included an international patent application for treating neurodegenerative diseases using rare cannabinoids filed early this month, as well as a notable quarter-over-quarter increase in the company’s cash, cash equivalents, and short-term investments from $7.4 million in Q4 2021 to $15.4 million in Q1 2022. InMed attributed this increase to the July 2 private placement in which the company received net proceeds of approximately $11.0 million. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• An ever-increasing demand for energy is fueling the focus on sustainable energy solutions.
• UUUU is proud to produce the raw materials that make numerous clean-energy and advanced technologies possible.
• Energy Fuels began producing rare earths in 2021, which are used in electric vehicles, renewable energy, batteries and other technologies.

As the world becomes more focused on and committed to clean energy and sustainability, companies in every sector are recognizing the importance of advancing ESG (environmental, sustainability, and governance) priorities. A leading U.S.-based uranium mining company Energy Fuels (NYSE American: UUUU) (TSX: EFR) places a high priority on its efforts to produce raw materials that support global clean-energy efforts. “As the world population continues to grow, there is an ever-increasing demand for energy, and renewable sources are the answer to providing sustainable energy solutions, while also protecting the planet from climate change,” states a TWI article. “The take-up of clean energy is not just happening on a national level as cities and states are also creating policies to increase renewable energy use. “In the United States, 29 states have set renewable energy portfolios to mandate that a certain percentage of energy consumed should come from renewable sources, and over 100 cities around the world now use at least 70% renewable energy,” the article continued. “The most important aspect of clean energy are the environmental benefits as part of a global energy future. “While clean, renewable resources also preserve the world’s natural resources, they also reduce the risk of environmental disasters, such as fuel spills or the problems associated with natural gas leaks,” the article states. “With fuel diversification, through different power plants using different energy sources, it is possible to create reliable power supplies to enhance energy security, ensuring there is enough to meet our demands.” With that as a backdrop, Energy Fuels does much more than just product uranium, which is the fuel for nuclear energy, producing 50% of all clean, carbon-free electricity in the U.S. “Energy Fuels is proud to produce the raw materials that make numerous clean energy and advanced technologies possible, all in the U.S. at the highest global standards for health, safety and environmental protection,” noted UUUU president and CEO Mark Chalmers (https://ibn.fm/nLhFh). In addition to producing uranium, the fuel for carbon- and emission-free nuclear energy, UUUU began operations to recover rare earth elements (“REEs”) in 2021, which are used in electric vehicles, renewable energy, batteries and other clean technologies. Also worth noting is that, in 2019, the company was the largest U.S. producer of vanadium, which is used in steel, high-strength alloys and grid-scale batteries. Finally, in addition to its efforts to produce material, Energy Fuels is committed to preserving global resources and addressing climate change through industry-leading recycling programs. Not a company to rest on its laurels, Energy Fuels is also exploring other business opportunities, including evaluation the recovery of medical isotopes for use in emerging cancer therapies from existing process streams. Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and began commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Hiring the wrong individual or placing a good candidate on the wrong team holds dire consequences for organizations.
• PPI evaluates, improves a company’s workforce, brand and culture by revealing the personality traits and sentiment buried in human expression.
• With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture.

Hiring the right talent and personality for a job is vital for employees — and employers — to be engaged and happy in the workplace, yet it can be hard to know when the person and position are perfect for each other. According to a Forbes article, artificial intelligence (“AI”) technology may be just what companies need to make those types of decisions (https://ibn.fm/2kqCo). That’s good news for DigiMax Global (CSE: DIGI) (OTC: DBKSF), an artificial intelligence technology and services company, whose Projected Personality Interpreter can be effectively used by employees to identify the ideal employees. “Hiring the wrong individual or placing a good candidate on the wrong team holds dire consequences for organizations, including lost productivity and diminished workplace morale,” Forbes reported. “According to the State of the American Workplace report by Gallup Inc., 51 percent of American workers are ‘not engaged’ in their work and an additional 16 percent are ‘actively disengaged’ in their work. “This dissatisfaction adds up to real money for corporations with Gallup estimating that an actively disengaged employee costs their organization $3,400 for every $10,000 of salary, or 34 percent. Furthermore, in hot job markets, such as the technology sector, employers are also spending heavily on additional benefits such as meals, transportation and fitness facilities. Even with these perks, turnover is high.” The article went on to discuss DIGI’s Projected Personality Interpreter (“PPI”), originally conceived and launched by Darwin Ecosystems, a company that was acquired by DigiMax late last year (https://ibn.fm/e05oY). Based on the Darwin Analytics Engine, PPI evaluates and improves a company’s workforce, brand and culture by revealing the personality traits and sentiment buried in human expression (https://ibn.fm/V896c). By leveraging IBM Watson and a customer algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, PPI can provide HR personnel with complete information that supports and guides decision making and removes bias. With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture. “Employers can leverage the PPI service to understand if a job applicant has the right mix of personality traits for the role or to work within a specific team,” the article continued. “While many interviews focus on communications skills and previous work history, the PPI measures personality traits such as curiosity, susceptibility to stress and self-discipline levels. In a world that focuses on interviewing for the ‘hard skills’ of a job such as technical proficiency and metrics, it’s been difficult for companies to define interview protocols that uncover skills such as a sense of ethics, cautiousness and cooperation levels.” Employers aren’t the only ones that can use PPI. The platform is available as an app, enabling users to identify the personality projected by their social media footprint as well as blogs and web pages. Users can even submit student essays, research papers, work reports and executive summaries to measure the personality traits projected (https://ibn.fm/qMfTz). DIGI is an official IBM Watson partner, reselling or embedding Watson into applications and solutions that it offers. In addition to its deep expertise in AI, DigiMax’s engineering team boasts extensive experience in other key elements including machine learning, neural language processing, big data and cryptocurrency technology. For more information, visit the company’s website at www.DigiMax-Global.com. NOTE TO INVESTORS: The latest news and updates relating to DBKSF are available in the company’s newsroom at https://ibn.fm/DBKSF

• Avricore Health is developing a variety of pharmacy services that provide lab-quality testing for pre-diabetes and cardiovascular concerns
• The company’s trademarked HealthTab platform makes advanced testing technologies available to partner pharmacies and, through them, to patients at accessible point-of-care (“POC”) locations
• HealthTab’s partnership with Abbott Diagnostics in Canada also has the potential to expand to virus testing for COVID, RSV, influenza A and B, and strep
• The company has located the systems in Ontario and British Columbia through an agreement with large national pharmaceutical chain Shoppers Drug Mart, and anticipates expansion to other Shoppers Drug sites with 600 locations established by the end of 2023
• Avricore also expects to forge agreements that will take HealthTab’s POC testing to pharmacies in the United States, United Kingdom and European Union

Health diagnostics solutions innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating its achievement of key milestones this year, building on its initial agreement with Canada’s Shoppers Drug Mart pharmaceutical chain to make its platform technology accessible to patients across the country. Avricore’s milestones include building an agreement with Abbott Diagnostics to establish in-store kiosks that utilize Avricore’s platform, allowing Avricore to test its platform in pilot stage and roll it out to the ready Shoppers Drug Mart sites. Avricore’s HealthTab platform (www.healthab.com) is a testing and health data network that draws on data from blood samples and other samples utilizing Abbott’s trademarked Afinion 2 and ID Now instruments to provide lab-quality results to patients in real time. Avricore’s mission is to make such advanced testing technologies available to its partner pharmacies. Avricore’s efforts to provide access to the testing solution makes it possible for patients to seek out pharmacies in their local neighborhoods, often within walking distance, to gain insights on critical health conditions without the additional delays associated with getting clinic appointment and then having to visit a lab. Point-of-care testing is poised to become the natural evolution of the medical industry, delivering an alternate route to health management information as pharmacists trained to dispense medications and provide vaccinations add lab testing and results oversight (https://ibn.fm/6QYZe). After testing its pilot program in Ontario, Avricore added West Coast pharmacies in British Columbia. The company’s successes in those locations have led management to forecast it will set up POC in additional Shoppers Drug Mart locations across Canada, add other pharmacies in the United States, and continue to expand to the United Kingdom and European Union (https://ibn.fm/HvOVp). The company has stated it intends to set up its POC health testing kiosks in 600 locations by the end of 2023 (https://ibn.fm/fWW6m). Its site testing is initially just providing services for pre-diabetes and cardiovascular indications, linked to Ellerca Health Corp’s app-based digital platform for chronic disease management to provide better outcomes for patients who are self-managing their illnesses (https://ibn.fm/vp2mG). But the Abbott agreement also paves the way for potential testing and reporting for COVID’s SARS-CoV-2 virus, RSV, influenza A and B, and strep at the ID Now kiosks (https://ibn.fm/f1Baf). Two key aims of Avricore’s focus on making a range of health innovations available through the community pharmacy are to improve health outcomes for patients and lower overall healthcare costs going forward. Reducing the cost of routine lab tests may ultimately help reduce costs for insurers. Insurer Blue Cross and Blue Shield of North Carolina cut $112 million in laboratory spending in 2020 through better management of the testing, according to a Modern Healthcare report (https://ibn.fm/9dVh9). “I think we have known that laboratory testing has been a driver of costs for some time,” Blue Cross’s senior medical director over clinical effectiveness, John Campbell, told Modern Healthcare. “They’re now looking at the small dollar amounts and saying listen, the volume is such here, if we decrease costs by 1 percent, that equals X amount of dollars back to the insurer,” Mick Raich, president of revenue cycle management consulting at Charlotte, North Carolina-based Lighthouse Lab Services, said in the report. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• MCOA just signed an LOI with VapeTV UK and Jasleen Enterprises for the launch of VapeTV U.S.
• This new company is set to offer in-store advertising within retail vape stores
• It will capitalize on the growing CBD industry and the ever-increasing demand for in-store media advertising in the United States

Marijuana Company of America (OTC: MCOA) has announced the signing of a non-binding letter of intent (“LOI”) that marks the beginning of the process to form a new in-store advertising brand named VapeTV US, Inc. (https://ibn.fm/lmoux). VapeTV US will be the product of a three-way partnership among cDistro, Inc, a wholly-owned MCOA distribution company, VapeTV Ltd., a United Kingdom (“UK”)-based advertising company, as well as Jasleen Enterprises LLC, the owner of Vapor Maven, one of the leading online vape shops in the United States. MCOA, through cDistro, will own 25% of the company and will capitalize on its growing customer database, coupled with Vapor Maven’s over 200 retail locations to push its services. VapeTV UK has been Europe’s leading provider of in-house media for the vaping industry. Since its inception, it has made a name for itself providing in-store display systems that run paid advertising content within retail vape stores. With the signing of this LOI, VapeTV is excited about its entry into the largely untapped United States market. “We are excited to initiate the U.S. market version of the highly successful and lucrative VapeTV business. By launching with Vapor Maven’s nearly 200 retail locations and by leveraging cDistro’s active customer database of more than 65,000 retail vape stores in the U.S., we anticipate an accelerated delivery of VapeTV advertising content to U.S. customers,” noted Mike Shaw, the Founder of VapeTV UK. VapeTV US comes in the wake of the growing competition among thousands of individual vape, smoke, and CBD brands trying to push themselves in the market. This competition is driving up the demand for in-store media advertising, an opportunity that VapeTV plans to capitalize on going forward. This move aligns with MCOA’s commitment to diversifying its product and services, given its strategic investments within the cannabis THC, hemp, and CBD industries. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension
• HYPER-H21-4 will build on successes witnessed in initial human hypertension studies
• The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease
• Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology

With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of orally-delivered fat-soluble active pharmaceutical ingredients (“APIs”) through its patented DehydraTECH(TM) drug delivery technology  is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, Lexaria expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies, HYPER-H21-1 and HYPER-H21-2, that evidenced effective, sustained, and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approval from the Independent Review Board (“IRB”) for the study protocols around its fourth hypertension study. Described as the most ambitious study Lexaria has ever undertaken, HYPER-H21-4 will comprise 60 volunteers aged between 45 and 70 years, some of whom will be given three 150 mg doses of DehydraTECH-CBD daily for six weeks, while a subset will be given a placebo control. The extended duration is intended to enable the company to collect important data by monitoring the prolonged use of DehydraTECH-CBD and will investigate the potential for longer-term health benefits. “Outcomes from this study could support Lexaria’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” said Lexaria CEO Chris Bunka in a recent press release (https://ibn.fm/t9dFj). Notably, HYPER-H21-4 is just one of the many planned studies slated for 2022. Others include HOR-A22-1, a pharmacokinetic (“PK”) study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen; DEM-A22-1, an efficacy modeling study to evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia; RHEUM-A22-1, an efficacy modeling study to investigate the ability of DehydraTECH-CBD to potentially affect the treatment of rheumatoid disease; and DIAB-A22-1, an efficacy modeling study to explore DehydraTECH-CBD’s ability to potentially impact treatment of diabetes (https://ibn.fm/JCvyu). In addition to fulfilling Lexaria’s goal to enter into new, different multi-billion-dollar markets, the four animal studies will mark the company’s push to help patients living with these conditions, some of which are potentially fatal. According to the World Health Organization (“WHO”), diabetes was the ninth leading cause of deaths globally in 2019, having claimed an estimated 1.5 million lives (https://ibn.fm/AwduP). Additionally, WHO ranks dementia as the seventh leading cause of death among all diseases and a primary cause of dependency and disability, majorly among the elderly (https://ibn.fm/BLUjc). As a versatile solution with multiple benefits, DehydraTECH is protected by a robust portfolio of 23 granted patents (currently) and more than 50 pending patents. The technology works by combining APIs with long chain fatty acid oils such as high oleic sunflower oil. The product is then added to food/carrier particles before undergoing a dehydration synthesis procedure. The final step entails rendering the final form factor of the drug as a liquid or powder. According to Lexaria, “DehydraTECH works symbiotically with existing physiological systems to enable improved and more rapid absorption into the bloodstream and brain tissues” (https://ibn.fm/mRofm). Through its focus on improving how APIs enter the bloodstream by promoting healthier delivery methods, Lexaria remains committed to improving lives and lessening deaths associated with heart disease, cigarette smoking, and, with the new R&D programs, diabetes, dementia, and more. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Date: December 4-5, 2021 Venue: Chicago Hilton, 720 South Michigan Ave, Chicago, IL Exhibit Hall Hours

• Saturday, December 4th: 11:00 A.M. to 5:00 P.M.
• Sunday, December 5th: 10:00 A.M. to 4:00 P.M.

Onsite Box Office hours begin at 9:00 a.m. each day. Cannabis cultivators, dealers, businesses, and enthusiasts are invited to attend the NECANN Illinois Cannabis Convention in Chicago, on December 4-5, 2021. Operating since 2014, NECANN events are touted as one of the largest cannabis events that are constantly expanding. The NECANN events attract a huge number of members from the Hemp, MMJ and Cannabis industries. The success of the NECANN events is attributed to the exhibitors and attendees. Anden, Columbia Care, Green Mountain Energy, and a host of other eminent start-ups will be present at this rapidly expanding convention. Participants can gain immense knowledge about the latest trends in the cannabis industry from the influencers and distinguished speakers as well as the exhibitors displaying their products and services at the NECANN Chicago. NECANN aims to bring the stalwarts of the cannabis industry under one roof at the Chicago convention. With the approval of the Illinois Cannabis Regulation and Tax Act in 2019, Illinois became the first state in the U.S. to legalize recreational marijuana sales through legislation. Illinois is estimated to produce between $2 and $4 billion in annual income from recreational sales. Since legalization, Illinois is earning an average monthly revenue of $40 million from recreational cannabis sales. Do not miss out on this phenomenal opportunity to connect with some of the biggest names in the marijuana industry in this region! NECANN offers a wonderful arena to small industries, start-ups and new cannabis growers and dealers to discover new business prospects and build networking ties with established cannabis companies and investors. In addition to the exhibit hall, there will be four full programming tracks running each day (medical, business, opportunity, social equity & justice), where attendees can learn the latest trends and technologies in the marijuana industry. The Illinois Cannabis Convention is expected to witness the largest crowd of the local medical cannabis market as well as players foraying into the new adult-use recreational market. This convention presents the best B2B and B2C platform for cannabis businesses in the state, and for those trying to carve a niche in the Illinois marijuana spectrum! In addition, this convention serves as an education platform for those interested in learning more about the vital medical marijuana program in Illinois. For more information, visit https://ibn.fm/2h0NN